M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 8.5 PLN -0.7% Market Closed
Market Cap: 137.4m PLN
Have any thoughts about
Mabion SA?
Write Note

Mabion SA
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mabion SA
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
M
Mabion SA
WSE:MAB
Other Long-Term Assets
zł4.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-23%
R
Read Gene SA
WSE:RDG
Other Long-Term Assets
zł500.9k
CAGR 3-Years
N/A
CAGR 5-Years
3%
CAGR 10-Years
-6%
G
Genomed SA
WSE:GEN
Other Long-Term Assets
zł1.3m
CAGR 3-Years
107%
CAGR 5-Years
59%
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Other Long-Term Assets
zł140k
CAGR 3-Years
-82%
CAGR 5-Years
-66%
CAGR 10-Years
-41%
U
Urteste SA
WSE:URT
Other Long-Term Assets
zł121k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Other Long-Term Assets
zł3.5m
CAGR 3-Years
-26%
CAGR 5-Years
-19%
CAGR 10-Years
0%
No Stocks Found

Mabion SA
Glance View

Market Cap
137.4m PLN
Industry
Biotechnology

Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

MAB Intrinsic Value
13.69 PLN
Undervaluation 38%
Intrinsic Value
Price
M

See Also

What is Mabion SA's Other Long-Term Assets?
Other Long-Term Assets
4.7m PLN

Based on the financial report for Sep 30, 2024, Mabion SA's Other Long-Term Assets amounts to 4.7m PLN.

What is Mabion SA's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-23%

Over the last year, the Other Long-Term Assets growth was -65%.

Back to Top